Related Experiment Videos
Plasma exchange in chronic progressive multiple sclerosis: a long-term study
B O Khatri1, M P McQuillen, R G Hoffmann
1Medical College of Wisconsin, Milwaukee.
Neurology
|March 1, 1991
Summary
Plasma exchange combined with immunosuppressive drug therapy offers sustained benefits for chronic progressive multiple sclerosis patients. This extended study found significant long-term clinical improvement and no major life-threatening complications.
Area of Science:
- Neurology
- Immunology
- Clinical Medicine
Background:
- Previous studies indicated plasma exchange (PE) provides benefits for chronic progressive multiple sclerosis (CPMS) patients on immunosuppressive drug therapy (ISDT).
- Further investigation is needed to assess long-term efficacy, retreatment criteria, and toxicity of combined PE and ISDT.
Purpose of the Study:
- To evaluate the extended-term efficacy and safety of plasma exchange combined with low-dose immunosuppressive drug therapy in patients with chronic progressive multiple sclerosis.
Main Methods:
- Analysis of 200 CPMS patients treated with PE and low-dose ISDT over seven years.
- Assessment of clinical improvement using the Kurtzke Disability Status Scale.
- Evaluation of long-term follow-up data up to six years.
Main Results:
- Significant improvement in disability status was observed post-therapy and at 3-year follow-up compared to pre-treatment levels.
- Clinical improvement was maintained in the majority of patients for up to 6 years.
- No major life-threatening complications were attributed to the combined therapy.
Conclusions:
- Combined plasma exchange and low-dose immunosuppressive drug therapy demonstrates sustained clinical efficacy in CPMS patients.
- The treatment regimen appears safe for long-term use with no major adverse events observed.